Allarity Therapeutics Inc. Reports Third‑Quarter 2025 Financial Results and Business Updates
Allarity Therapeutics Inc. (NASDAQ: ALLT) announced its unaudited financial results for the third quarter ended September 30, 2025, along with updates on its clinical pipeline and corporate initiatives.
Key Financial Highlights
| Item | Q3 2025 | Q3 2024 |
|---|---|---|
| Cash and Cash Equivalents | $16.90 million | $19.53 million |
| Receivables from ATM sales | — | $1.42 million |
| Prepaid Expenses | $1.80 million | $0.51 million |
| Tax Credit Receivable | $1.66 million | $0.77 million |
| Total Current Assets | $20.47 million | $22.34 million |
| Current Liabilities | $8.79 million | $10.84 million |
| Total Liabilities | $8.79 million | $10.84 million |
| Net Property, Plant & Equipment | $330 k | $309 k |
| Total Assets | $20.80 million | $22.65 million |
The company’s balance sheet reflects a modest decline in liquidity, largely attributable to a reduction in cash and a shift in the composition of current assets. Current liabilities decreased as accounts payable and accrued expenses fell, partially offset by the elimination of the warrant derivative liability reported in the prior year.
Earnings per Share
Allarity reported a GAAP earnings per share of ‑$0.19 for Q3 2025, which is $0.04 better than expected according to market estimates. The negative earnings figure is consistent with the company’s status as a clinical‑stage biopharmaceutical firm, where research and development outpaces revenue generation.
Business Updates
- Clinical Pipeline: The company continues to advance its oncology programs. While specific milestones were not disclosed, Allarity reiterated its commitment to developing novel therapeutics for cancer patients in both the United States and Denmark.
- Corporate Strategy: Allarity remains focused on securing additional funding to support its research initiatives and maintain operational momentum. The company’s market capitalization stands at approximately $17.3 million, with a share price of $1.18 as of 2025‑11‑13.
- Financial Position: Despite a current market price below the 52‑week low of $0.61, the company’s liquidity is sufficient to support ongoing clinical activities. Its price‑earnings ratio is negative (‑0.65), reflecting its pre‑revenue status.
Outlook
Allarity Therapeutics expects to continue its research and development efforts while seeking strategic partnerships and additional capital. The company’s recent financial results demonstrate disciplined cash management, though they underscore the need for further investment to advance its therapeutic candidates.
All information is sourced from Allarity’s third‑quarter 2025 financial release and associated press coverage dated 2025‑11‑14.
